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Introduction
Autosomal dominant polycystic kidney disease (ADPKD) 
constitutes the most common genetic kidney disease in 
the world and affects 1 per 1000 subjects [1]. The num-
ber of people suffering from ADPKD in Poland could be 
estimated at about 30,000–40,000. Most of them progress 
to ESRD during their lifetime when renal replacement 
therapy (RRT) is required. According to the Report on the 
Renal Replacement Therapy in Poland, in 2011, ADPKD 
was the fourth leading cause of ESRD, with a prevalence 
rate of 8.6 %, following diabetes mellitus (DM), primary 
glomerulonephropathies, and arterial hypertension [2]. 
Similarly, in other European registries, ADPKD accounts 
for 4.2–12.6 % of all patients currently treated with RRT 
[3].
Over the past 20 years, due to improved survival of 
ESRD patients, the number of ADPKD patients receiving 
RRT markedly increased [4]. As in other nephropathies, 
the decision on the type of dialysis modality in patients 
with ADPKD is usually based on the patient’s choice, phy-
sician’s experience, or preferences, as well as resource 
availabilities.
Faced with the decision on the best dialysis option, 
many physicians are reluctant to choose peritoneal dialy-
sis (PD), due to the potential disadvantages of the method 
in this patients’ population: risk of hernias and fluid leak-
ages, risk of peritonitis and cyst infection, or insufficient 
dialysis adequacy. However, most studies reporting the risk 
of the above-mentioned complications have not provided 
even estimated data on the incidence or prevalence. Thus, 
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the exact risk is largely unknown. Depending on the source, 
peritoneal leakage episodes were reported in 14.2 or 15 % 
of the ADPKD patients, but varied from 0.25 to 11.8 % in 
non-ADPKD groups [5, 6]. Reported abdominal wall her-
nias needed surgical intervention, but there were no differ-
ences in the requirement for temporary use of HD in both 
groups. All ADPKD patients with abdominal hernias were 
reported to be able to resume PD after surgical repair [7].
The concept of an integrated approach to RRT assumes 
that in most cases, PD ought to be considered as a treat-
ment option. However, in many centers, this is not the case 
for patients with ADPKD. This is mainly due to concerns 
for the possible impaired dialysis efficacy due to enlarged 
kidneys that potentially reduce the available effective peri-
toneal surface area [8]. Furthermore, the risk for abdominal 
wall hernias and peritoneal leaks is thought to be increased. 
Finally, owing to an increased incidence of diverticuli-
tis in ADPKD, the risk of peritonitis, especially with the 
Gram-negative bacteria, might be augmented. Whether 
these threats outweigh benefits of PD in ADPKD patients 
is debatable. According to recent data, adjusted mortality 
decreased by 45 % in ADPKD patients starting PD, while it 
decreased by only 25 % in those starting HD during the last 
20 years [4].
The aim of the present study was to clarify whether 
the efficacy and the course of PD therapy in patients with 
ADPKD varies from that observed in subjects with ESRD 
due to other nephropathies, based on the data from the Pol-
ish Peritoneal Dialysis Registry (PPDR).
Methods
We conducted a cross-sectional survey based on the data 
from the PPDR, which included information on subjects 
treated with PD in 63 dialysis centers all over the coun-
try. The registry acts under the Polish Society of Nephrol-
ogy and data are voluntarily put in a computer database. 
Data are recorded at the initiation of PD and every year 
thereafter.
The study cohort consisted of 2394 incident PD patients. 
The inclusion period was between 2006 and 2013. For 
the present analysis, patients underwent a follow-up for a 
maximum of 5 years from the start of dialysis until death, 
technique failure or censoring. The data obtained from the 
PPDR included patient’s age, gender, primary renal dis-
ease, comorbidities, basic laboratory results, as well as data 
on the medication used, methods, and adequacy of dialy-
sis. Hypertension and DM were comorbidities collected 
in the registry. Hypertension was defined as a blood pres-
sure >140/90 mmHg or if the patient was taking antihyper-
tensive medications. DM was diagnosed if patients were 
using insulin or oral hypoglycemic agents or if the fasting 
glucose concentration was >126 mg/dL, twice. Laboratory 
values collected in the registry comprised blood levels of 
hemoglobin (g/dL), albumin (g/L), calcium (mg/dL), and 
phosphorous (mg/dL). Dialysis adequacy was assessed 
using 24-h dialysate and urine collection with a calcula-
tion of total weekly Kt/V. Peritoneal transport was assessed 
using the standard peritoneal equilibration test. Of all the 
repeated measures in an individual patient (laboratory val-
ues, dialysis adequacy, etc.), the most recent were used for 
the analysis. For comparisons, the weekly dose of eryth-
ropoiesis-stimulating agents (ESA) in patients not taking 
erythropoietin-beta was converted into erythropoietin-beta 
units.
Patients included in this study were all subjects over 
18 years of age, recorded in PPDR and treated with chronic 
PD due to end-stage renal disease. Patients were included 
in the ADPKD group based on the registry records, and 
diagnosis of the disease was left for the discretion of the 
attending physician. Exclusion criterion was the lack of a 
definite diagnosis of the underlying kidney disease.
The outcomes examined were technique failure, sur-
vival, and occurrence of complications: peritonitis epi-
sodes, tunnel infections, exit-site infections, hernias, and 
peritoneal fluid leakages.
Technique failure was defined as a permanent cessation 
of PD due to PD-related complications. For the technique 
survival analysis, patients were censored at transplantation, 
death, recovery of renal function, or when completing the 
follow-up period. Technique survival status was censored 
at the end of the follow-up period, i.e., September 12, 
2014. Survival was determined from the initiation of PD 
treatment, and the patients were followed for a maximum 
of 5 years, with a median follow-up period of 32 months. 
For the patient survival analysis, subjects were censored at 
transplantation, transfer to HD, recovery of renal function, 
or when completing the follow-up period. Survival status 
was censored on September 12, 2014.
The diagnosis of peritonitis was made on the basis of 
white blood cell count >100/µL in peritoneal fluid efflu-
ent or Gram-positive stain or bacterial culture from the 
effluent. Exit-site infection was defined according to the 
standard scoring by Twardowski [9]. Tunnel infection was 
defined clinically as the presence of tenderness and indura-
tion or ultrasonographically as an evidence of fluid collec-
tion along the catheter.
Statistical analysis
Results are expressed as mean and standard deviation or 
median and interquartile range, as appropriate. A P value 
<0.05 was considered to be statistically significant. Com-
parisons between two groups were assessed for continuous 
variables with a Student’s unpaired t test, or Mann–Whitney 
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test, as appropriate. For categorical variables, a Chi-square 
test was utilized.
Survival analyses were made with the Cox propor-
tional hazard model. The relative risks for mortality were 
determined by multivariate Cox regression analysis and 
presented as hazard ratios [hazards ratio (HR); 95 % con-
fidence intervals (CI)]. The statistical analysis was per-
formed using statistical software Statistica version 7.1 
(StatSoft Inc.).
Results
The study population consisted of 2394 patients included 
in the registry between 2006 and 2013. From this cohort, 
we excluded 682 patients because of the lack of diagno-
sis or the diagnosis not established. Patient’s demographic 
and baseline characteristics were not significantly different 
between excluded and further analyzed group.
Thus, we analyzed data of 1712 patients, where 106 
patients were diagnosed with ADPKD, and the remaining 
group of 1606 subjects consisted of patients with a diagno-
sis of diabetic nephropathy (33.3 %), primary glomerulone-
phritis (26.8 %), hypertensive nephropathy (11.8 %), tub-
ulointerstitial nephritis (11.6 %), and other (16.5 %). The 
general characteristics of the ADPKD and the non-ADPKD 
subjects are presented in Table 1. Patients suffering from 
ADPKD were, on average, older and had a greater propor-
tion of women, as compared to the non-ADPKD group. 
The basic laboratory parameters, as well as the dialysis ade-
quacy and peritoneal membrane permeability, did not differ 
significantly between the groups. Information on dialysis-
associated complications was reported by 18 PD centers. 
These patients (N = 732) did not differ significantly from 
the other participants in terms of the basic clinical charac-
teristics (not shown). The data on the dialysis-associated 
complications in this subset of analyzed patients are pre-
sented in Table 2. The risk of peritonitis was comparable 
Table 1  General characteristics 
of the autosomal dominant 
polycystic kidney disease 
(ADPKD) and non-autosomal 
dominant polycystic kidney 
disease patients treated with 
peritoneal dialysis
ADPKD Autosomal dominant polycystic kidney disease, APD automated peritoneal dialysis, D:P 
dialysate/plasma index, ESA erythropoiesis-stimulating factor, PD peritoneal dialysis
ADPKD (n = 106) Non-ADPKD (n = 1606) P value
Age (years) 62 (55–72) 60 (47–71) 0.04
Gender (% male) 42.5 53.3 0.05
Mean time PD treatment (months) 44.3 46.3 0.6
PD modality (% of APD) 45.3 44.4 0.9
Renal transplantation (%) 26.4 18.6 0.04
Transferred to HD (%) 18.9 21.4 0.5
Renal function recovered (%) 0 1.2 0.3
Superimposed diabetes mellitus (%) 11.3 9.6 0.6
Hypertension (%) 83.0 83.9 0.9
Albumin (g/L) 37.3 ± 6.0 36.0 ± 7.3 0.1
Ca × P 46.9 ± 13.6 45.9 ± 14.1 0.7
Hemoglobin (g/dL) 11.4 ± 1.5 11.2 ± 1.7 0.2
Need for ESA (%) 73.6 75.2 0.7
Mean ESA dose (U/week) 3351 ± 1918 3524 ± 2159 0.5
Kt/V 2.22 ± 0.59 2.33 ± 0.71 0.2
D:P creatinine (4 h) 0.65 ± 0.13 0.68 ± 0.14 0.1
Table 2  Dialysis-associated 
complications in the autosomal 
dominant polycystic kidney 
disease (ADPKD) and non-
autosomal dominant polycystic 
kidney disease patients
All data reflect the number of patients
ADPKD (n = 37) Non-ADPKD (n = 695) P value
Peritonitis 25 464 0.8
Peritonitis rate (episode per patient months) 1 per 32 1 per 25 0.8
Tunnel infection 2 (5.4 %) 23 (3.3 %) 0.8
Exit-site infection 3 (8.1 %) 58 (8.3 %) 0.8
Hernia 2 (5.4 %) 16 (2.3 %) 0.5
PD fluid leak 3 (8.1 %) 26 (3.7 %) 0.4
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in the two groups, as was the risk for other complications. 
It has to be stressed that the risk of abdominal hernias and 
of dialysis fluid leaks was twice as high in the ADPKD 
group, as compared to the controls, and did not reach statis-
tical significance mainly due to the low numbers of patients 
affected by these complications.
The maximal follow-up time was 5 years with a median 
observation period of 32 months. Since the groups were 
different with respect to age and gender, we performed a 
Cox proportional hazard analysis which included these and 
other potential confounders (Table 3). It demonstrated that 
ADPKD was not associated with a different risk for poor 
outcome in comparison with the other nephropathies. Mor-
tality rates were 5.8 deaths/100 patient-years in ADPKD 
and 6.3 in non-ADPKD group. Technique survival was 
also evaluated with the Cox proportional hazard analysis, 
as demonstrated in Table 4. The overall technique failure 
rates were 18.9 and 21.4 % in ADPKD and non-ADPKD 
group, respectively. As with the patient survival, ADPKD 
showed absolutely no associations with the risk of tech-
nique failure.
Since the presence of DM turned out to be an independ-
ent predictor of all-cause mortality, we repeated all the 
above-mentioned analyses following exclusion of diabetic 
patients. However, the results concerning the clinical and 
laboratory data, as well as the outcome, did not change 
substantially (not shown). Also, we found no difference in 
the risk of dialysis-associated complications or the treat-
ment outcome between APD and CAPD subjects.
Discussion
The present study, based on a large national registry, evalu-
ates mortality and technique survival in a relatively large 
ADPKD population treated with PD. It reveals that the 
dialysis adequacy, represented in this study by weekly urea 
Kt/V, calcium phosphate product, as well as by hemoglobin 
levels, and the need for ESA, is not different in the ADPKD 
patients, as compared to the non-ADPKD controls. Fur-
thermore, the patient and technique survival is similar in 
the ADPKD and non-ADPKD subjects. The results argue 
against the above-mentioned concerns related to the appli-
cability of PD in the ADPKD population. Moreover, they 
stay in accordance with some previous reports in other 
ADPKD cohorts. In a study by Kumar et al. [10], PD ther-
apy long-term outcomes were identical in patients with 
ADPKD and in non-diabetic matched controls. In a Chi-
nese cohort of 42 consecutive ADPKD patients, the 5-year 
patient and technique survival was not different from that 
of 84 matched non-ADPKD controls [7]. Also, on the basis 
of the results of the multicenter prospective matched-cohort 
study of 106 ADPKD patients and 312 controls, Janeiro 
et al. [6] have concluded that PD is a suitable RRT option 
in ADPKD. On the other hand, we should take into account 
that some selection bias might occur, as patients with an 
advanced organomegaly might not be qualified for PD in 
most centers. Recently, Hamanoue et al. [11] have evalu-
ated the influence of kidney and liver volumes on continu-
ation of PD in patients with ADPKD. They have concluded 
that PD performance may be limited in patients with very 
enlarged organs, due to abdominal hernias and leaks of 
dialysis fluid. Clearly, this shows a need for a large registry 
collecting data on total kidney volume, liver volume, cyst 
infections, etc.
In our observation, the risk of abdominal hernias and 
dialysis fluid leaks was twice as high in the ADPKD groups 
than in the other patients, a difference that did not reach 
statistical significance due to the low number of events, 
but surely is of clinical importance. These results stay in 
accordance with other studies confirming that these com-
plications constitute a considerable problem in ADPKD 
PD patients [7, 11–13]. However, both our study and the 
previous evaluations document that in a vast majority of 
patients, hernias and fluid leaks are treatable, as they are 
not associated with a permanent transfer to hemodialy-
sis. It has to be underlined that the number of hernias and 
leaks was relatively low in our study. Similar results were 
obtained in a study by Hadimeri et al. [14] in which the 
risk of developing hernia was, similarly, twice as high in 
ADPKD patients, but the difference did not reach statistical 
significance. Other studies showed similar proportions but 
higher rate of these complications [7].
Table 3  Cox proportional hazard analysis for all-cause mortality 
(n = 1712; ADPKD 106; non-ADPKD 1606)
HR (95 % CI) P value
ADPKD 0.76 (0.41–1.40) 0.4
Age 1.05 (1.04–1.06) <0.001
Gender 1.10 (0.84–1.44) 0.5
Diabetes mellitus 1.54 (1.18–2.01) 0.002
Hypertension 0.50 (0.37–0.70) <0.001
Table 4  Cox proportional hazard analysis for peritoneal dialysis 
technique failure (n = 1712; ADPKD 106; non-ADPKD 1606)
HR (95 % CI) P value
ADPKD 1.04 (0.64–1.68) 0.9
Age 1.00 (0.99–1.00) 0.4
Gender 0.81 (0.64–1.01) 0.07
Diabetes mellitus 1.09 (0.86–1.39) 0.5
Hypertension 1.30 (0.92–1.84) 0.14
1743Int Urol Nephrol (2015) 47:1739–1744 
1 3
The risk of other PD-related complications, especially 
peritonitis, was similar in both groups. Concerns for the 
potentially higher risk of peritonitis in ADPKD patients 
treated with PD have originated from the fact that diver-
ticulitis is relatively common in the course of this disease. 
However, the studies performed to date show similar results 
to the present evaluation, with no difference in the peritoni-
tis rate between ADPKD and non-ADPKD groups [7, 15, 
16].
We found no difference in the proportion of PD modali-
ties (APD vs. CAPD) in ADPKD patients as compared to 
non-ADPKD group. Due to reduced intraperitoneal pres-
sure in APD technique, this method of treatment seems to 
be preferred in ADPKD individuals in some centers [16]. 
In a recent report by Janeiro et al. [6], the percentage of 
ADPKD patients treated with APD has been no different as 
compared to other nephropathies.
We have expected the dose of ESA to be lower in 
ADPKD, as synthesis of erythropoietin in polycystic kid-
neys is maintained even at late stages of the disease. It has 
proven not to be the case as there has been no difference 
between the groups in this respect.
The major limitation of the present study is the ret-
rospective nature of the current analysis. We also have to 
state that our study is confirmatory in nature, as studies 
have already been conducted in this field, as discussed 
above. Nevertheless, in our opinion, these data from a large 
national cohort add to our understanding of the evaluated 
issue. Another potential limitation is that the evaluation 
is based on a registry data, which might be influenced by 
underreporting. However, even if it had been the case, it 
would have affected both the ADPKD and non-ADPKD 
patients. Therefore, it should not bias the relative compari-
sons. Our data on peritonitis do not include the pathogen 
identification. Thus, we were unable to assess the rate of 
peritonitis episodes caused by Gram-negative bacteria, 
potentially more prevalent in the course of diverticulitis. 
Finally, although the data were based on a national regis-
try, the number of subjects was still rather low, resulting 
in a lack of sufficient statistical power to identify certain 
clinically meaningful differences between the groups, 
as, for instance, the risk of abdominal hernias. It should 
be noted that on the basis of the registry data, we are not 
able to provide and analyze additional information regard-
ing PD complications, as, for example, the information on 
kidney and liver volume, or the influence of the time of 
commencement of PD following catheter placement on the 
occurrence of peritoneal leakages. Selection bias should 
be also considered, as PD might not be offered to a pro-
portion of ADPKD patients due to some actual or poten-
tial contraindications. The observation time of a maximum 
5 years might be regarded as rather short, although with a 
high mortality rate typical for dialysis patients, as well as a 
high dropout due to transplantations, it is sufficient, in our 
opinion, for reliable conclusions.
According to the ERA–EDTA Registry, the relative con-
tribution to RRT of PD equals 5.8 % in ADPKD patients, 
while it is as high as 7.1 % in the non-ADPKD subjects 
[4]. Simultaneously, the increase in the transplantation 
rate has been noted in this group [4]. The relatively lower 
prevalence of PD in ADPKD might be due to the above-
mentioned concerns. Although most probably it is a con-
sequence of the higher proportion of transplanted patients 
among the ESRD subjects with ADPKD, compared to 
patients with other nephropathies, it still shows the degree 
of underutilization of PD treatment in the ADPKD popula-
tion. Unfortunately, this trend can be also observed in our 
country. According to the Report on the Renal Replace-
ment Therapy in Poland, the proportion of ADPKD patients 
treated with PD constituted only 4 % of dialyzed subjects 
in 2011 [3]. The present study demonstrates that the dialy-
sis adequacy, and patient and technique survival are similar 
in the ADPKD and non-ADPKD patients treated with PD. 
PD seems a feasible treatment option for end-stage renal 
failure in the course of ADPKD and should be always con-
sidered as an important element of an integrated therapeu-
tic approach.
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